- Home
- SKIL vs LITS Comparison
SKIL vs LITS Comparison
Compare SKIL & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKIL | LITS |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | United States |
| Employees | 2247 | 4 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 41.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SKIL | LITS |
|---|---|---|
| Price | $7.99 | $1.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 215.1K | ★ 219.6K |
| Earning Date | 04-07-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.43 | $0.95 |
| 52 Week High | $23.00 | $3.03 |
Technical Indicators
Market Signals| Indicator | SKIL | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 63.57 | 48.02 |
| Support Level | $3.63 | $1.12 |
| Resistance Level | $8.53 | $1.16 |
| Average True Range (ATR) | 0.99 | 0.05 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 77.75 | 29.29 |
Price Performance
Historical ComparisonAbout SKIL Skillsoft Corp.
Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.